If you’re on the hunt for stocks to watch today, Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) is a stock to give close attention to. The company shares are trading 2.92% or 0.024 points down from last closing price of $0.83, reaching $0.8058 at last check. The EKSO share price has dropped in 4 of the last 5 days and is down -57.71% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -217,777 shares, and in total 92423 shares valued at $74474 were seen changing hands compared with 310200 shares valued at $257466 recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the EKSO stock is near its bottom.
Ekso Bionics Holdings, Inc. (EKSO) shares have notched a 3-month decline of about -57.71%, but has still tumbled -31.45% year to date. By comparison, the stock sank -67.68% over the past 12 months, while it slipped -32% over the 1 month. The company’s market cap is around $67.01M, with its short interest ratio standing at 5.49%.
In the current trading session for EKSO, the stock witnessed two major price actions, it rose to a high of $0.8385 and was down as much as $0.8 at one point. The high recorded is very low when compared to their 52-week high which is $0.81. The 52-week high is now at -75.45 distance from current price. Their recent low of $3.3 represents a -0.01% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for EKSO is $2.9, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of Ekso Bionics Holdings, Inc. earned $-0.32 per share in the trailing 12 months and has a P/E ratio of -2.52. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 31.72 and lower compared to the sector’s average of 32.67. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. EKSO also has P/S multiple of 5. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 6.55x.
The company recorded an interesting insider purchase transaction by the Director on May 23, 2018. A Securities and Exchanges Commission filings show that Steven Sherman bought a total of 200,000 EKSO shares that day for a sum of around $302,000. Ekso Bionics Holdings, Inc. (EKSO) insiders have acquired no shares in the stock within the past three months. In total, individual insiders traded 51,159 shares in the business, which makes up 44.042% of 116,159 shares that were traded over a year. In the past 12 months, insiders have purchased 65,000 shares while the seller parted with 51,159 shares.
EKSO‘s last price was down -54.56% as compared to the average trading price of 50 days recorded at $1.77 while enlarging the period to 200 trading days, the average closing price was $1.2. At present, there are 78.84 million in the total number of common shares owned by the public and among those 74.24 million shares have been available to trade. The percentage of shares being held by the company management was 0.1% while institutions stake was 39%. The company has generated negative returns on equity over the last 12 months (-454.3%). It managed to keep its gross profit margin at 45% over the past 12 months.
When assessing the full upside of the EKSO stock, there is another set of technicals that should be looked into and considered. Its -24.78% decline from moving average of $1.07 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 1.76 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.